ClinicalTrials.Veeva
Menu

Find clinical trials for COVID-19 in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Infections
Communicable Diseases
Coronavirus Infections
Pneumonia
Post-Acute COVID-19 Syndrome
Human Influenza
Respiratory Tract Infections

COVID-19 trials near Hanyang, Seoul, KOR:

Efficacy and Safety of ES16001 in Patients With COVID-19

legal age for adult in each country) with confirmed mild or moderate COVID-19 tested positive with a real time reverse transcriptio...

Enrolling
COVID-19
Drug: ES16001 80 mg
Drug: ES16001 40 mg

Phase 2, Phase 3

Genencell

Seoul, Korea, Republic of and 2 other locations

Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID...

Enrolling
COVID-19 Pneumonia
Drug: NuSepin® 0.4 mg/kg
Drug: Placebo

Phase 2, Phase 3

Shaperon

Incheon, Namdong-gu, Korea, Republic of

seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.It also contains a sub-study to enroll patients with severe COVID...

Enrolling
COVID-19
Parainfluenza
Drug: DAS181 COVID-19
Drug: DAS181

Phase 3

Ansun Biopharma

Seoul, Gyeonggi-do, Korea, Republic of and 59 other locations

The safety and immunogenicity of AdCLD-CoV19-1 OMI (5.0x10\^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old a...

Active, not recruiting
COVID-19
Vaccines
Biological: AdCLD-CoV19-1 OMI (Part B)
Biological: AdCLD-CoV19-1 OMI (Part A)

Phase 1, Phase 2

Cellid

Seoul, Korea, Republic of and 6 other locations

known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.The aim of the Phase I/III study (Parent Study) will -...

Active, not recruiting
COVID-19, SARS-CoV-2
Biological: AZD3152 (Parent study Main Cohort)
Biological: AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152

Phase 2, Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 214 other locations

This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) ...

Active, not recruiting
SARS-CoV-2
Biological: Placebo
Biological: GLS-5310

Phase 1, Phase 2

GeneOne Life Science

Seoul, Korea, Republic of

The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy vo...

Active, not recruiting
SARS-CoV-2
Drug: Saline
Drug: GX-19

Phase 1, Phase 2

Genexine

Seoul, Korea, Republic of

The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy vo...

Active, not recruiting
SARS-CoV-2
Drug: GX-19N
Drug: Placebo

Phase 1, Phase 2

Genexine

Seoul, Korea, Republic of and 4 other locations

This is a first in human, phase I, open-label, dose-escalation study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Vaccine...

Enrolling
COVID-19
Biological: IN-B009 (High-dose)
Biological: IN-B009 (Low-dose)

Phase 1

HK inno.N
HK inno.N

Seoul, Korea, Republic of and 2 other locations

This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infe...

Active, not recruiting
Pneumonitis
SARS-CoV Infection
Drug: Placebo
Drug: GLS-1027

Phase 2

GeneOne Life Science

Seoul, Korea, Republic of and 16 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems